SELLAS Life Sciences (SLS) announced that clinical data from its ongoing Phase 2 study of SLS009, a highly selective CDK9 inhibitor, in ...

SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one ...

The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.

We came across a bullish thesis on Sellas Life Sciences Group Inc (SLS) on ValueInvestorsClub by ContraMundem. In this article we will summarize the bulls’ thesis on SLS. Sellas Life Sciences shares ...

SLS Hotels & Residences has unveiled its first all-inclusive property, the SLS Playa Mujeres, located just 15 miles north of Cancun International Airport. Situated in a gated beachfront community, the ...

NEW YORK, Nov. 30, 2023 /PRNewswire/ -- SOCOTEC USA, a leading provider of TIC (Testing, Inspection, and Certification), consulting, and advisory services with a strategic focus on buildings and ...